Hybrid Sulfonylurea-Linked Chalconoids as Antidiabetic Agents: Evaluation of Antihyperglycemic Effects in Streptozotocininduced Type 2 Diabetic Rats

Raju, D. Bhagya; Rao, A. Vasudeva; Prasad, Y. Rajendra

doi:10.31788/rjc.2018.1133084

Cited by 1 publication

(1 citation statement)

References 39 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several authors have evaluated the antihyperglycemic activity of synthetic chalcones in streptozotocin-induced diabetic rats ( Satyanarayana et al, 2004 ; Shukla et al, 2007 ; Najafian et al, 2010 ; Rawat et al, 2011 ; Mahapatra et al, 2017a ; Sengupta et al, 2017 ; Shukla et al, 2017 ; Tajammal et al, 2017 ; Acharjee et al, 2018 ; Naidu, 2018 ; Raju et al, 2018 ). It was found that these compounds have a moderate to potential ability to reduce blood sugar.…”

Section: Preclinical Pharmacological Activities Of Chalconesmentioning

confidence: 99%

Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence

et al. 2021

View full text Add to dashboard Cite

Chalcones are among the leading bioactive flavonoids with a therapeutic potential implicated to an array of bioactivities investigated by a series of preclinical and clinical studies. In this article, different scientific databases were searched to retrieve studies depicting the biological activities of chalcones and their derivatives. This review comprehensively describes preclinical studies on chalcones and their derivatives describing their immense significance as antidiabetic, anticancer, anti-inflammatory, antimicrobial, antioxidant, antiparasitic, psychoactive, and neuroprotective agents. Besides, clinical trials revealed their use in the treatment of chronic venous insufficiency, skin conditions, and cancer. Bioavailability studies on chalcones and derivatives indicate possible hindrance and improvement in relation to its nutraceutical and pharmaceutical applications. Multifaceted and complex underlying mechanisms of chalcone actions demonstrated their ability to modulate a number of cancer cell lines, to inhibit a number of pathological microorganisms and parasites, and to control a number of signaling molecules and cascades related to disease modification. Clinical studies on chalcones revealed general absence of adverse effects besides reducing the clinical signs and symptoms with decent bioavailability. Further studies are needed to elucidate their structure activity, toxicity concerns, cellular basis of mode of action, and interactions with other molecules.

show abstract